Groupama Asset Managment Grows Holdings in AstraZeneca PLC (NASDAQ:AZN)

Groupama Asset Managment lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 22.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 543,398 shares of the company's stock after purchasing an additional 101,225 shares during the quarter. Groupama Asset Managment's holdings in AstraZeneca were worth $42,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. Dynamic Advisor Solutions LLC increased its stake in shares of AstraZeneca by 48.9% in the second quarter. Dynamic Advisor Solutions LLC now owns 13,816 shares of the company's stock valued at $1,077,000 after buying an additional 4,535 shares during the period. Sequoia Financial Advisors LLC lifted its holdings in shares of AstraZeneca by 6.2% during the second quarter. Sequoia Financial Advisors LLC now owns 30,263 shares of the company's stock worth $2,360,000 after purchasing an additional 1,777 shares during the period. Diversified Trust Co grew its stake in shares of AstraZeneca by 22.7% in the second quarter. Diversified Trust Co now owns 5,330 shares of the company's stock worth $416,000 after purchasing an additional 987 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in AstraZeneca by 2.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 186,152 shares of the company's stock valued at $14,518,000 after purchasing an additional 4,551 shares during the period. Finally, TRUE Private Wealth Advisors bought a new position in AstraZeneca during the 2nd quarter worth $215,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have commented on AZN. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a "sell" rating to a "hold" rating in a research report on Wednesday, November 6th. Erste Group Bank raised shares of AstraZeneca from a "hold" rating to a "buy" rating in a research report on Wednesday, September 11th. TD Cowen boosted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Monday, August 12th. Finally, UBS Group upgraded shares of AstraZeneca from a "sell" rating to a "neutral" rating in a research report on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $89.75.

AstraZeneca Stock Down 2.0 %

Shares of AZN stock traded down $1.40 on Tuesday, reaching $67.18. 3,531,131 shares of the company were exchanged, compared to its average volume of 5,308,330. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The company has a market cap of $208.30 billion, a price-to-earnings ratio of 32.81, a PEG ratio of 1.22 and a beta of 0.45. The company has a 50-day moving average of $71.09 and a 200-day moving average of $77.01. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the company posted $0.87 earnings per share. The company's quarterly revenue was up 18.0% on a year-over-year basis. Analysts anticipate that AstraZeneca PLC will post 4.11 earnings per share for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.